Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Angelini Pharma

  • Home
  •  
  • Angelini Pharma



  • Most Read
  • Latest Comments
  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AFT to launch Maxigesic Rapid in the United States after IV launch in Feb
    AFT to launch Maxigesic Rapid in the United States after IV launch in Feb
    • News

  • AFT Pharmaceuticals locks in $9.4 million agreement after US FDA approves pain relief drug Maxigesic IV
    AFT Pharmaceuticals locks in $9.4 million agreement after US FDA approves pain relief drug Maxigesic IV
    • News

  • AFT’s pain relief medication Maxigesic gets FDA approval, but the IV version still under scrutiny
    AFT’s pain relief medication Maxigesic gets FDA approval, but the IV version still under scrutiny
    • News

  • High Court sides with AFT Pharmaceuticals after Nurofen maker dispute
    High Court sides with AFT Pharmaceuticals after Nurofen maker dispute
    • News

  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication
    AFT Pharmaceuticals gains regulatory approval for new form of pain medication
    • News

  • AFT Pharmaceuticals gains regulatory approval for new form of pain medication
    • News

    AFT Pharmaceuticals gains regulatory approval for new form of pain medication

    Fresh off their recent distribution success of their intravenous, non-opioid based pain medication, AFT Pharmaceuticals (ASX: AFP) has ticked another box announcing the receival of regulatory approval for another form of the drug. The oral liquid form of Maxigesic is a non-opioid based analgesic and extension of AFT’s patented Maxigesic family of medications. The oral

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.